# InflaRx Announces Participation in February Investor Conferences
Canonical URL: https://biopharmsignal.com/news/IFRX/inflarx-announces-participation-in-february-investor-conferences-35349363
Ticker: IFRX
Company: Inflarx NV
Source: Inflarx NV
Published: 2026-01-29 12:30 EST
## Summary

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by...

## Article Body
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in several investor conferences in February 2026. Details are as follows:

Guggenheim Securities Emerging Outlook: Biotech Summit 2026 February 11 - 12, 2026 in New York, NY Fireside chat on Wednesday, February 11 at 11:30 AM ET

InflaRx will also conduct one-on-one investor meetings on February 11 th . A link to view the fireside chat live stream and its replay is available here .

Oppenheimer 36th Annual Healthcare Life Sciences Conference February 25 - 26, 2026 in a virtual format Virtual presentation on February 25 at 8:40 AM ET

InflaRx will also conduct one-on-one investor meetings on February 25 th . A link to view the virtual presentation and its replay is available here .

About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa (HS). The Company has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de . InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

| InflaRx N.V. | MC Services AG |
| --- | --- |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |

FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
## Recent Company News
- 2026-06-30 11:30 EST — [InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos](https://biopharmsignal.com/news/IFRX/inflarx-assessing-feasibility-of-broadened-strategy-for-anca-associated-vasculit-7f39d900) — Source: Inflarx NV
- 2026-05-08 12:15 EST — [InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares](https://biopharmsignal.com/news/IFRX/inflarx-announces-closing-of-150-million-underwritten-offering-of-ordinary-share-085761a8) — Source: Inflarx NV
- 2026-05-06 12:30 EST — [InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares](https://biopharmsignal.com/news/IFRX/inflarx-announces-pricing-of-150-million-underwritten-offering-of-ordinary-share-36e34ae6) — Source: Inflarx NV
- 2026-05-06 12:25 EST — [InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases](https://biopharmsignal.com/news/IFRX/inflarx-announces-advancement-of-izicopan-in-anca-associated-vasculitis-and-sele-3cdb784a) — Source: Inflarx NV
- 2026-05-04 11:30 EST — [InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes](https://biopharmsignal.com/news/IFRX/inflarx-reports-favorable-reactive-metabolite-profile-for-izicopan-in-human-live-6c0b8eb5) — Source: Inflarx NV
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)